OHM1

Research use only, not for human use.

OHM1 is a potent HIF1α mimic that binds to CH1 domain of p300/CBP with Kd of 500 nM.

OHM1 is a potent HIF1α mimic that binds to CH1 domain of p300/CBP with Kd of 500 nM, reduces the level of HIF1α transcriptional activity under hypoxia to that observed under normoxia at 20 uM in A549 cells; reduces the median tumor volume in murine tumor xenografts, and does not cause measurable changes in animal body weight or other signs of toxicity in tumor-bearing animals.

RT-PCR Cell Line:A549 Concentration:10 μM Incubation Time:24 h Result:Down-regulated the mRNA expression levels of the critical angiogenesis regulator vascular endothelial growth factor (VEGFA) by 80%. Decreased lysyl oxidase (LOX) and glucose transporter 1 (GLUT1) expression.

Animal Model:BALB/c mice, MDA-MB-231 xenograft model Dosage:15 mg/kg Administration:Intraperitoneal injection, every other day for 15 injections Result:Reduced the median tumor volume by roughly 50% compared with the untreated group. Did not cause measurable changes in animal body weight or other signs of toxicity in tumor-bearing animals, nor increased the metastasis rate.

OHM 1

Angiogenesis

HIF/HIF Prolyl-hydroxylase

HIF/HIF Prolyl-hydroxylase

——

——

1450995-09-1

494.637

C24H42N6O5

>98% (HPLC)

——

——

(S)-2-((S)-4-((S)-2-((S)-3-isobutyl-2-oxopiperazin-1-yl)-4-methylpentanoyl)-3-methyl-2-oxopiperazin-1-yl)pentanediamide

(-20℃)

With Ice Pack

≥ 2 years